COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			12 Months Ended
	Feb. 28, 2022	Dec. 10, 2021	Dec. 31, 2022	Dec. 31, 2018	Dec. 31, 2016	Mar. 31, 2023
Loss Contingencies [Line Items]
Purchase obligation						$ 586,000
Number of common stock issued			400,000
Number of additional shares issued			100,000
Harborside Advisors LLC [Member]
Loss Contingencies [Line Items]
Stock issued during period, shares, reverse stock splits		1,000,000
Stock issued during period, shares, stock splits		200,000
Stockholders' equity, reverse stock split		5-for-1
Revenue		$ 10,000,000
Shares issued		1,000,000
Incurred damages		$ 75,000
Harborside Advisors LLC [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency, damages sought, value		33,000,000.0
Harborside Advisors LLC [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Loss contingency, damages sought, value		$ 5,000,000.0
Conversion Labs Rx Business [Member]
Loss Contingencies [Line Items]
Stock issued during period, shares, stock splits		200,000
Conversion Labs Rx Business [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Stock issued during period, shares, stock splits		1,000,000
Pilaris Laboratories, LLC [Member]
Loss Contingencies [Line Items]
Finite-lived intangible asset, useful life					10 years
Intercompany agreements, description					As consideration for granting Conversion Labs PR this license, Pilaris will receive on quarterly basis, 10% of the net income collected by the licensed products based on the following formula: Net Income = total income – cost of goods sold – advertising and operating expenses directly related to the marketing of the licensed products
Percentage of net income					10.00%
Accrued expenses			$ 138,000			$ 0
M.ALPHABET, LLC [Member]
Loss Contingencies [Line Items]
Intercompany agreements, description				The Company shall pay Alphabet a royalty equal to 13% of Gross Receipts (as defined in the Agreement) realized from the sales of Licensed Products. No amounts were earned or owed as of March 31, 2023
Share based compensation arrangement by share based payment award, expiration period				10 years
Stock option to purchase shares				20,000
Stock option exercise price				$ 2.50
M.ALPHABET, LLC [Member] | Common Stock One [Member]
Loss Contingencies [Line Items]
Stock option to purchase shares				20,000
Stock option exercise price				$ 2.50
Proceeds from issuance of common stock				$ 7,500,000
M.ALPHABET, LLC [Member] | Common Stock Two [Member]
Loss Contingencies [Line Items]
Stock option to purchase shares				20,000
Stock option exercise price				$ 2.50
Proceeds from issuance of common stock				$ 10,000,000.0
M.ALPHABET, LLC [Member] | Common Stock Three [Member]
Loss Contingencies [Line Items]
Stock option to purchase shares				40,000
Stock option exercise price				$ 3.75
Proceeds from issuance of common stock				$ 20,000,000.0
Conversion Labs Rx Business [Member]
Loss Contingencies [Line Items]
Contigency contract amount		$ 274,000
Conversion Labs Rx Business [Member] | Harborside Advisors LLC [Member]
Loss Contingencies [Line Items]
Stock issued in issuance costs		5,000,000
Conversion Labs Rx Business [Member] | Harborside Advisors LLC [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Stock issued in issuance costs		$ 5,000,000
Blair LLC [Member]
Loss Contingencies [Line Items]
Contigency contract amount	$ 1,000,000.0